NCT03835949
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with active or untreated brain or leptomeningeal metastases- see trial for details; Patients with prior T-cell therapy
https://ClinicalTrials.gov/show/NCT03835949